Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Preferred Stock Liabilities (2019 - 2021)

Historic Preferred Stock Liabilities for P3 Health Partners (PIII) over the last 3 years, with Q4 2021 value amounting to $47.0 million.

  • P3 Health Partners' Preferred Stock Liabilities changed N/A to $47.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $47.0 million, marking a year-over-year change of. This contributed to the annual value of $47.0 million for FY2021, which is N/A changed from last year.
  • Per P3 Health Partners' latest filing, its Preferred Stock Liabilities stood at $47.0 million for Q4 2021.
  • P3 Health Partners' 5-year Preferred Stock Liabilities high stood at $52.7 million for Q1 2021, and its period low was $47.0 million during Q2 2021.
  • For the 3-year period, P3 Health Partners' Preferred Stock Liabilities averaged around $48.8 million, with its median value being $47.3 million (2019).
  • Over the last 5 years, P3 Health Partners' Preferred Stock Liabilities had its largest YoY gain of 852.1% in 2020, and its largest YoY loss of 852.1% in 2020.
  • Over the past 3 years, P3 Health Partners' Preferred Stock Liabilities (Quarter) stood at $47.6 million in 2019, then increased by 8.52% to $51.6 million in 2020, then dropped by 8.85% to $47.0 million in 2021.
  • Its last three reported values are $47.0 million in Q4 2021, $47.0 million for Q3 2021, and $47.0 million during Q2 2021.